Avanos Medical (AVNS) EV to EBITDA (2014 - 2026)

Avanos Medical has disclosed EV to EBITDA across 13 years of filings, most recently posting 66.1 for Q1 2026.

• In Q1 2026, EV to EBITDA rose 20.38% year-over-year to 66.1; the TTM figure through Mar 2026 stood at 9.34 (down 543.75% YoY), while the FY2025 annual figure was 7.01, down 345.17% from the prior year.
• EV to EBITDA came in at 66.1 for Q1 2026 at Avanos Medical, down from 172.76 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 4660.81 in Q3 2025 to a low of 531.07 in Q2 2023.
• Average EV to EBITDA over 5 years is 343.15, with a median of 84.61 recorded in 2024.
• Year-over-year, EV to EBITDA slumped 556.74% in 2023 and jumped 11686.25% in 2025.
• Over 5 years, EV to EBITDA stood at 68.15 in 2022, then climbed by 24.19% to 84.64 in 2023, then sank by 101.76% to 1.49 in 2024, then surged by 11686.25% to 172.76 in 2025, then plunged by 61.74% to 66.1 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 66.1 in Q1 2026, 172.76 in Q4 2025, and 4660.81 in Q3 2025.